AstraZeneca's ($AZN) MedImmune has licensed a toll-like receptor (TLR) agonist from 3M ($MMM), in the hopes that intratumoral injection of the candidate will allow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback